Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Fulgent Genetics (FLGT) 10K Form and Latest SEC Filings 2026

Fulgent Genetics logo
$15.85 +0.15 (+0.96%)
Closing price 05/18/2026 04:00 PM Eastern
Extended Trading
$15.14 -0.71 (-4.47%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Fulgent Genetics SEC Filings & Recent Activity

Fulgent Genetics (NASDAQ:FLGT) has submitted 392+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Fulgent Genetics's financial statements. The most recent filing was a Form 4 submitted on May 18, 2026.

Form 4
Fulgent Genetics, Inc. Reports Ownership Change on May. 18, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-K
Fulgent Genetics Files Annual Report on Feb. 27, 2026

The 10-K contains Fulgent Genetics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Fulgent Genetics SEC Filing History

Browse Fulgent Genetics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/18/2026 5:51 PM
Fulgent Genetics (1674930) Issuer
Nohaile Michael (1890563) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 5:30 PM
Fulgent Genetics (1674930) Issuer
GROVES REGINA E (1653877) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 5:30 PM
Dong Linda (1765204) Reporting
Fulgent Genetics (1674930) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:59 PM
Fulgent Genetics (1674930) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/28/2026 3:51 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 3:52 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 3:52 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 3:55 PM
Fulgent Genetics (1674930) Subject
Hsieh Ming (1302110) Filed by
Form SCHEDULE 13D/A
03/31/2026 3:57 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Ming Hsieh Trust (1836339) Reporting
Form 4/A
03/31/2026 3:16 PM
Fulgent Genetics (1674930) Filer
Form ARS
03/31/2026 3:11 PM
Fulgent Genetics (1674930) Filer
Form DEF 14A
03/31/2026 3:13 PM
Fulgent Genetics (1674930) Filer
Form DEFA14A
03/11/2026 4:24 PM
Fulgent Genetics (1674930) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 4:24 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:00 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:00 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:01 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:01 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2026 6:04 AM
Fulgent Genetics (1674930) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2026 6:15 AM
Fulgent Genetics (1674930) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/25/2026 7:17 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 7:17 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 7:18 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2026 7:18 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 4:05 PM
Fulgent Genetics (1674930) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
12/22/2025 3:11 PM
Fulgent Genetics (1674930) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2025 4:04 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 4:04 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 4:04 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 8:12 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/01/2025 8:13 PM
Fulgent Genetics (1674930) Subject
Gao Hanlin (1684532) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/01/2025 8:14 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 8:14 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 6:00 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 6:00 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 7:26 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2025 7:24 PM
Fulgent Genetics (1674930) Subject
Gao Hanlin (1684532) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 5:36 PM
Fulgent Genetics (1674930) Subject
Gao Hanlin (1684532) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 5:37 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 7:03 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/07/2025 6:14 AM
Fulgent Genetics (1674930) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)

Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel

See how to get positioned in SpaceX before the announcement goes public
11/07/2025 6:10 AM
Fulgent Genetics (1674930) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/28/2025 4:20 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2025 4:20 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2025 4:20 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/20/2025 5:04 AM
Fulgent Genetics (1674930) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/03/2025 4:29 PM
Fulgent Genetics (1674930) Subject
Gao Hanlin (1684532) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/03/2025 4:29 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/03/2025 4:31 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:33 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:33 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 5:55 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 5:55 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 5:55 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 5:55 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 8:13 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144/A
08/27/2025 8:13 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144/A
08/27/2025 6:47 PM
Fulgent Genetics (1674930) Subject
Gao Hanlin (1684532) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/27/2025 6:49 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2025 6:10 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 6:11 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 6:12 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2025 6:13 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/25/2025 7:24 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/01/2025 6:05 AM
Fulgent Genetics (1674930) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2025 6:09 AM
Fulgent Genetics (1674930) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/29/2025 5:04 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 5:04 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 5:04 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/29/2025 3:23 PM
Fulgent Genetics (1674930) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
06/11/2025 3:30 PM
Fulgent Genetics (1674930) Issuer
Hsieh Ming (1302110) Reporting
Ming Hsieh Trust (1836339) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:46 PM
Fulgent Genetics (1674930) Issuer
Xie Jian (1819718) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:47 PM
Fulgent Genetics (1674930) Issuer
Gao Hanlin (1684532) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 3:47 PM
Fulgent Genetics (1674930) Issuer
Kim Paul (1253820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 3:49 PM
Fulgent Genetics (1674930) Subject
Xie Jian (1819718) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2025 6:29 PM
Fulgent Genetics (1674930) Issuer
Marsh Linda (1765204) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 4:32 PM
Fulgent Genetics (1674930) Issuer
GROVES REGINA E (1653877) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 4:32 PM
Fulgent Genetics (1674930) Issuer
Nohaile Michael (1890563) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Fulgent Genetics SEC Filings - Frequently Asked Questions

Fulgent Genetics (FLGT) has submitted 392+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Fulgent Genetics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Fulgent Genetics's financial statements page.

The most recent filing was a Form 4 submitted on May 18, 2026. This was an insider ownership change filed by 4 - Fulgent Genetics, Inc. (0001674930) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:FLGT) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners